Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879722 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT01879722 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 77 participants.
The verdict
NCT01879722, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
Interventions
- DRUG TAK-063
- DRUG TAK-063 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01879722
The ClinicalTrials.gov registry entry for NCT01879722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-063 is the first listed.
NCT01879722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01879722 about?
NCT01879722 is a clinical study titled "Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants". The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
What is the current status of trial NCT01879722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2013-06. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01879722?
The interventions under investigation include: TAK-063 (DRUG), TAK-063 Placebo (DRUG).
Who is sponsoring clinical trial NCT01879722?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.